Table 3 Results: univariate analysis.
Overall (n = 551) | No RUX (n = 274) | No or lost response to RUX (n = 104) | RUX (response) (n = 91) | p = value | |
|---|---|---|---|---|---|
Non-relapse mortality (at 1 year) | 21.9% (95% CI: 18–25) | 22.9% (95% CI: 18–28) | 25.5% (95% CI: 17–34) | 14.8% (95% CI: 7–22) | 0.16 |
Median days to neutrophil engraftment (range) | 17 (5–83) | 17 (7–57) | 17 (10–81)) | 17 (5–83) | 0.43 |
Acute GVHD II–IV | 28.9% (95% CI: 25.1–32.8) | 28.9% (95% CI: 23.4–34.4) | 27.5% (95% CI: 18.8–36.1) | 27.0% (95% CI: 17.7–36.2) | 0.92 |
Chronic GVHD (at 2 years) | 46.7% (95% CI: 42.2–51.2) | 41.7% (95% CI: 35.4–48.0) | 55.7% (95% CI: 45.2–66.2) | 50.7% (95% CI: 40.0–61.3) | 0.11 |
Chronic GVHD extensive disease | 29.2% (95% CI: 24.7–33.6) | 25.5% (95% CI: 19.8–31.1) | 37.9% (95% CI: 27.5–48.3) | 30.6% (95% CI: 20.8–40.4) | 0.08 |
Overall survival at 2 years | 63.2% (95% CI: 59.1–67.2) | 60.8% (95% CI: 55.0–66.6) | 57.5% (95% CI: 48.0–67.1) | 70.0% (95% CI: 60.5–79.5) | 0.15 |
Relapse at 2 years | 16.3% (95% CI: 13.2–19.5) | 19.1% (95% CI: 14.3–23.9) | 15.7% (95% CI: 8.6–22.7) | 8.1% (95% CI: 2.3–13.8) | 0.05 |
Event-free survival at 2 years | 56.5% (95% CI: 52.3–60.8) | 53.7% (95% CI: 47.7–59.8) | 49.9% (95% CI: 40.2–59.6) | 68.9% (95% CI: 59.2–78.7) | 0.01 |
